Estrella Immunopharma, Inc. (NASDAQ:ESLA) Financings

Estrella Immunopharma, Inc.

Financings

RaiseDate
Registered direct offering of common stock and pre-funded warrants with concurrent private placement common warrants
Closed: US$8M raised · US$1.58 a share · Warrants at US$1.39 for 60 months · Aegis Capital Corp.
Dealers: Aegis Capital Corp. (lead)
Use of proceeds: General corporate purposes and working capital
Jan 6, 2026
Private placement of shares of common stock
Announced: about US$3.35M · US$1.5 a share
Use of proceeds: Complete Phase I of the STARLIGHT-1 trial of EB103 in adults with relapsed/refractory B-cell non-Hodgkin's lymphoma
Jun 3, 2025

Read by 6ix AI from the company's releases